All News

Eculizumab, a humanized monoclonal antibody, was first approved for adults with generalized myasthenia gravis in 2017.

Untargeted lipidomics identified a glycerophospholipid and sphingolipid signature that differentiated severe alcohol-related hepatitis (sAH) from decompensated cirrhosis (DC).

A new free resource provides clear insights on contracted rates, enabling pharmacies to fill the community care gap.

Although the 16-week end point was not met, tezepelumab demonstrated meaningful effects in patients with chronic spontaneous urticaria (CSU) after 32 weeks.

Use of dexamethasone over tocilizumab was associated with significant cost-savings for patients with relapsed/refractory multiple myeloma (RRMM).

A strong knowledge of pharmacology and clinical pharmacotherapeutics is essential for sports pharmacists, enabling them to support athletes' overall health while ensuring compliance with anti-doping regulations.

Compared with daily oral iron, a single intravenous (IV) infusion of iron was shown to lower rates of low birth weight in infants and decrease reliance on further iron supplementation or transfusions in pregnant patients with anemia.

The pandemic showcased the resiliency and adaptability of pharmacists.

The health care community was left largely unaware of the controversy that occurred at one of the clinical trial sites.

Vepdegestrant is an experimental oral PROteolysis TArgeting Chimera that degrades estrogen receptor (ER) in patients with metastatic breast cancer.

The study aims to assess how docosahexaenoic acid levels in cerebrospinal fluid relate to both neurodegeneration and cognitive function.

The favorable outcomes were observed in the phase 3 AMPLIFY trial.

Results of the POETYK PsA-2 trial indicate deucravacitinib’s effectiveness at reducing the severity and burden of symptoms in patients with psoriatic arthritis.

Although improvements were observed in blood pressure (BP) medication adherence, there were no improvements in stain or glucose-lowering medication use.

Patients may have concerns about the boxed warning and other potential adverse effects associated with topical ruxolitinib for atopic dermatitis and vitiligo.

Though rare and typically presenting as transient, a case study demonstrates severe, chronic neutropenia in a patient with multifocal motor neuropathy treated with intravenous immunoglobulin (IVIG).

Wafa Samara, PharmD, vice president and chief pharmacy officer at City of Hope, highlights the vital role of oncology pharmacists at City of Hope in improving patient outcomes, conducting and leading research, and working as integral members of the multidisciplinary care team.

If approved, vutrisiran would be the first FDA-approved therapy to treat both the polyneuropathy and cardiomyopathy aspects of transthyretin amyloidosis (ATTR).

Icotrokinra, an oral pill that blocks the IL-23 receptor, had a favorable safety profile in adults and adolescents 12 years and older with moderate-to-severe plaque psoriasis.

Even when safe, oral supplement use may not be appropriate to use during cancer treatment or recovery.

COVID-19 changed the personal and professional lives of all pharmacy workforce members. But what now?

Long-acting injectables offer a promising approach to schizophrenia treatment, but their effective use requires careful management and patient education.

In older postmenopausal women, leukocyte count was found to be an independent predictor of long COVID symptom severity, highlighting its potential for use as a novel symptom biomarker.

Currently, EN001 is undergoing evaluation in a phase 1b trial.

AI can streamline biosimilar adoption by simplifying prescribing decisions and reducing costs.